ASXL1 and myelodysplastic syndrome: Compared with patients without ASXL1 frameshift mutations, patients with ASXL1 frameshift mutations had a worse prognosis in MDS‐LB patients (median OS, not reached, p = 0.043; Figure 5E), but not in MDS‐IB patients (median OS, 31 vs. 15 months, p = 0.81; Figure 5F).